Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for behavioural problems in TSC, Fragile X syndrome, and Sanfilippo syndrome
NL-OMON58698Phase 3Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tuberous sclerosis complex (TSC), Sanfilippo syndrome and Fragile X syndrome (FXS) comparing Cannabidiol with Placebo (2 arms). Primary endpoint: Primary efficacy: irritability. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
tuberous sclerosis complex (TSC)Sanfilippo syndromeFragile X syndrome (FXS)
Beyond the preview
Go deeper on NL-OMON58698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58698.